Single Topic Workshop

White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance

We are excited to announce the release of our latest white paper, now available in the Journal of Hepatology. This paper delves into the crucial topic of hepatocellular carcinoma (HCC) risk stratification and surveillance, as presented at the recent ILCA Single Topic Workshop.

Our esteemed members have contributed their valuable insights and expertise, offering a unique perspective on how to shape the progress of liver cancer research and treatment.

Read the paper

Thank you for attending the “Single-Topic Workshop: HCC Risk Stratification and Surveillance” last 9-10 June, 2022 in Paris, France.

The Single Topic Workshop featured great sessions and lively debates from leading scientists and liver cancer specialists. We learned about the history of HCC surveillance research, novel biomarkers, potential alternative strategies to ultrasound, current challenges for HCC screening and type of cohort studies needed to define the high-risk population and validate biomarkers, and much more. Overall, this field looks very promising, but there’s still a lot of work and trials to be done.

Couldn’t attend? We have made the presentations available for ILCA members only courtesy of Fujifilm. Simply click on the button below and log in with your member credentials.

ACCESS THE ON-DEMAND RECORDINGS

BECOME A MEMBER

Single Topic Workshop Is About:

The past few years have seen significant changes in the management of liver cancer and the Single Topic Workshop initiative was established in recognition of the rapidly changing therapeutic landscape. Each STW will focus on a specific area in which recent developments have transformed the field of HCC. ILCA aims to provide delegates with state-of-the-art lectures delivered by leading experts and anticipate that these meetings will be of interest to all disciplines engaged in delivering care to patients with liver cancer.

Discuss recent advances in risk stratification and concepts of precision screening
Learn about proven and proposed strategies for chemoprevention
Hear about emerging biomarker and radiomic strategies for HCC screening, diagnosis, and prognostication
Engage with experts about emerging concepts in HCC surveillance and how best to promote early detection
Discuss patient and industry perspectives on HCC risk stratification and early detection

Who Should Attend?

Clinical and translational researchers, clinicians (primarily GI/hepatology), and industry representatives interested in HCC prevention, early detection or biomarkers. Talks may have Western focus (cirrhosis instead of HBV) although can interest delegates from Asia.

The Programme

Thursday 09 June 2022

TIME	SESSION	SPEAKER
13:00 – 13:15	Welcome & Introduction by the STW Co-chairs	Tim Meyer & Amit Singal
13:15 – 13:40	Risk stratification biomarkers – are we close?	Yujin Hoshida
13:40 – 14:05	Risk stratification after resection: Can we tailor surveillance for recurrence	Eric Vibert
14:05 – 14:30	HCC chemoprevention: Current options and the horizon	Neehar Parikh
14:30- 15:00	Panel Discussion	All
15:00 – 15:20	Coffee Break
15:20 – 15:45	Biomarkers for HCC diagnosis	Josep M. Llovet ➡ Session Abstract
15:45 – 16:10	Biomarkers for HCC prognosis and treatment response	Tim Meyer
16:10- 16:35	Radiomics for HCC diagnosis and prognosis on day	Maxime Ronot
16:35 – 17:05	Panel Discussion	All

Friday 10 June 2022

TIME	SESSION	SPEAKER
08:30 – 08:50	HCC surveillance – current recommendations and supporting evidence	Maria Reig
08:50 – 09:10	HCC surveillance utilization and potential interventions	Nicole Rich
09:10 – 09:30	Limitations of HCC surveillance test effectiveness and alternative imaging	Valerie Vilgrain
09:30 – 09:50	Precision screening for HCC: Is it possible and what do we need?	Pierre Nahon
09:50 – 10:20	Panel Discussion	All
10:20 – 10:40	Coffee Break
10:40 – 11:00	Phases of biomarker validation	Jorge Marrero
11:00 – 11:20	Emerging serum biomarkers for early HCC detection	Amit Singal ➡ Session Abstract
11:20 – 11:40	cfDNA for early HCC detection	Augusto Villanueva
11:40 – 12:10	Panel Discussion	All
12:10 – 13:30	Lunch
13:30 – 13:50	Patient advocacy perspective	Andrea Wilson
13:50 – 14:05	Bench to bedside: commercialization of biomarkers	Jeff Winick
14:05 – 14:20	Bench to bedside: commercialization of biomarkers	Marilyn Olson ➡ Session Abstract
14:20 – 14:30	Closing by the STW Co-chairs	Tim Meyer & Amit Singal

Meet the Chairs

Dr. Amit Singal
STW Co-Chair / UT Southwestern Medical Center, USA

Dr. Tim Meyer
STW Co-Chair / UCL Cancer Institute, University College, UK

Meet the Speakers

Augusto Villanueva

Jeffrey Winick

Andrea Wilson

The Venue

The workshop will take place in Holiday Inn Paris–Porte De Clichy Hotel

located in Paris’ north-western gateway district at the centre of “Grand Paris” project, an area where many international companies and future Judicial Precinct are located.

Partners & Supporters

ILCA warmly thanks all partners for their unrestricted support to the single-topic workshop and their commitment to help advance liver cancer science.

ILCA Industry Partners

If your organisation wishes to partner with ILCA and take part in the Single-Topic Workshop, please contact Jas Sidhu at [email protected] for sponsorship and exhibition opportunities. For media partnership, please contact Paulina Linares at [email protected].